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Conclusions: 1) LOTS pts show non-stationary TWA more frequently 
than stnllonan/ TWA, Usually. 30-40 boats out of 128 wore alternating. 2) 
Our correlative method was more effective thnn SM In non.stationary TWA 
detection, 3) Non.stntlonnry TWA is associated with higher henri rate, 
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~ Trestment of Patients With Hyparcholesterolemlc 
~nd Without Coronary Disease With Pravastetln 
i )eer~ssee Thrombue Format ion Under Dynamle 
Flow Condltlona 
G Dang(~s, J A, Ambrose, D,A, Smith, A,H, Un0~r, C. Fief, JH, Shno, 
P, Memi, J,T, Fallen, J,H, Chesobre, J,J, Bndimon, CaM~ova~c.lar Instmae. 
Mount SInni School of Medlcfne, N,~w York, USA 
Backgt~und: Lowonng cholesterol (C) ducroases platolel reactivity *n core. 
~ary d~soa~ (CAD) patients, but ~t~ affect on non.CAD patients l~an not boon 
previously descllbod, 
Mefho~l,~: We prospectively studied 40 stable pnl~ont~ wlll~ untreated 
LDL.C - 145 mg/dl CAD pntlonts received Pravnstatm (Pray), add non-CAD 
patlonls were rondoml..'ed to Pray vs Placebo (da~iblo.bllnd) All patients 
wore on AHA step I dial Tltrombus formalion w~s assessed blif~dly with a 
prevleusly valld,11od oX.vlvo pellUSlOn chamber system: nen.aalicoagulatod 
blood w~s passed directly from the pntienl's veln over a 8tnodnrd subslrnto 
(poroine nellie medin), under oontrellod theologic condlt,ons mlmicktng mild 
arterlnl stenosls (shoat rate 16908 ~) Poduslens wore podom~od at base- 
I~no, 3, and 6 months, Spoclmnos were stamod with CME, and for fibrmogon 
The oross.socllennl Ihrembus area (TA, in am" . t0 '~) way pl~nimotorod 
Re.qul~: Beth Pray groups shewed decreased LDL.C by 30",, wilhm 6 
w~ok~ (1Be to 126 mg/dl, p - 0,001 vs baseline), nnd decreased TA (table) 
Placebo produced no chnnges in either LDL-C or TA .',LDL-C and ,',TA wore 
modestly correlated (r - 0,49: p - 0005). 
~t~t3ohoo TA 3 f!lol'dh "[A (~ inonll'l TA 
Pray, .CAD(n. t6t 125 t ~ 1 109 t 29' 105 i 38"" 
Pray, CAD(n= 121 146 t 34 118 t ~3"  104 ~ 28"" 
Plclcebo, CAD (n = 12) 1221 19 1281~7 132145 
' p , n 07, " p • 004 vs basohno Values ,:,in moon I SD 
Conclusion: Pray therapy signill~;antly decreased ox-wvo thrombus lorma- 
tton in high LDL-C pallents, with and without CAD, This may. m part, explain 
ff~o beneficial effects el Pray m primary as well as secondary prevention of 
CAD 
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~ Lipid Lower ing Therapy  Reduces Blood 
Thrombogenlclty In Hypemholesterolemlc Patients: 
Effect of  S lmvastat ln  
U, Rauch, J.J. Badimon, DA. Vomhheimer, L Guzman, K, Harris, P. Harris, 
D.A, Sandier, J,T. Fallen, V, Fuster, J,H, Chesebro. Cardiovascular Institute. 
Meant Sinai School of Medscine, New York. NY LISA 
Lipid reduction ~mproves chmcal outoome of CAD patients despite minor 
angiographtc plaque regression. Normalization of endothehal function and 
plaque stabilization are two of the proposed mechanisms, We hypothesize 
that lipid reduction modulates blood thrombogenlcity. Blood thrembogenicity 
was measured as thrombus formation (THR) in an ex viva perlusion chamber. 
Hyperlipidemic patients (10 with and 5 without CAD) with total cholesterol 
(Cho) -.220 m~dl and LDL ~ 140 mg/dl at baseline and after 3- months 
treatment with simvastatin (20 me/day) were studied, Blood was perfused 
directly trem the psttent into the chamber at shear conditions typical of a 
mild coronary stenosts (1690/s) for 5 minute periods, Porcine aortic tuni~a 
media (model of severe arterial injury) served as the thrombogenic sub- 
strate Thrombus formation was measured as area !Hm2/mm), analyzed by 
2 independent blinded observers using computer-assisted planimetr~. 
Pallents basel':,.,: 3-months 
Cho LDL Thromt~us Cho LDL Thrombus 
CAD 253 189 10482 167" 106' 8605' 
No-CAD 277 205 9988 183' 110" 7891' 
All P15 261 172 10317 194" 108' 8366' 
• p - 005 
Lipid reduction by 8tmwlstntin reduces blood thrombogenicity, It was 
proviously suggosled that this effect is exclusive to pmvasttltin, Our rOsuffs 
indicate thrd the antlthrombotto effect t8 mediated by lipid reduction and 
Independent ol Ilto hypol*pidemic agent used, 
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~ Elevation of Plasmlnogen Activator Inhibitor "~/pe-1 
(PAl-l) in Normal Subjects by Induction of 
Hyperlnmullnemle With Hyperglycemia end 
Hypertrlglyeerldemla 
J, Calles.Eat~andon, S, Mirt, a, I~,E, ~obot, D J  Schnoide_r, Umver~i~., at
Vermont, Ehlrllngfon, V~, USA 
Hypofibrinolysis caused by Increased PAl.1 l!as boon implicated in the yes. 
culopathy of type ~ diabetes, typified by lnoroased insulin, g!gcose and 
triglycnrides, HowovQr, short 10rm infusions el insulin have not increased 
PAI.I in normal subie(~ts. We hylPothesi:'ed that induction el increased m. 
sulin accompanied by increased glucose and tnglycondos would lacrosse 
PAl.l, Acco~ingty 30%, glucose and 10% !ntrallpid wore infused tot 6 hours 
In tO normal lean Indlvld.als (54 t 3 y) resul!ing in inc~feased insuhn (42 
5 t~U/dL), ghlcose (200 ! 24 regfdl) and tnglycondos (425 t 45 mg~dl) 
simulating changes In lypo 2 d,abateS. 
R~sldt,'~. In c~ntrast o results wllh Inluslon el sahna alone [n = lb) and 
noglycemtc bypesnsullnemlc lamps (n = 10, serum insulin -= 8g ~- 7 j~UfdL), 
PAI.I m bleed increased signtlicanl!y 6 hr alter the onset el infusion t l5 
5 ngtml, p . 0.0,5 vs basohno = 74 t 11, saline 6 hr = 3.4 .* 1 I and 
msuhn 31; ,o 0 hr = 3.7 t 0.8) and remtlmod elevated for an additional 6 hr 
(combined infusion = 130 t 3~0 ng~ml, sahne = 6.7 1 2 ng'ml, insulin alone 
= 7,0 t 1 7 ng!ml, p = 006). 
Concl¢tstons: Our data suggest thai combmed hyPeensulinomia, hyper- 
tnglyeondemia and hyperglycemia m likely to contobute to bypolibenob/sls 
of type 2 diabetes by increasing the blood levels el PAl-1. Moreover, these 
instills undomcore the potential importance el moddymg insulin resistance 
as well as achieving glycemic and Iipidomic control in individuals wOh lype 2 
diabetes 
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[844-41 Benef ic ia l  Ef fect  of Estrogen Therapy on 
Flbrinotysis Is Independent of Changes in 
Low-Density Llpoprotein Levels 
KK. Koh, MN Bui, L. Hathaway. R.O. Cannon III NHLBI. NIH. Bethesda. 
MD. USA 
We have previously shown that oral coniugated equine estrogen (CEE) 
reduces ptasminogen activator Inh~b~tor (PAl-l) levels m postmenopausal 
women, an effect associated wdh proportionate increases .r degradabon 
products of fibnn However, oral estrogen reduces tow-density Itpopmtem 
cholesterol (LDL-C) levels that may account for PAl-1 effects, as oxidized 
LI.JL stimulates endothelial synthesis el PAl-1 in cell culture expenments. 
To assess the importance el LDL on PAl-l, we administered CEE 0.62,5 
me, slmvastatin 10 me, or the combination daily for 6 weeks each to 2,5 
hypemholesterolemic (LDL = 165 :~ 37 mg/dL; mean ± SD) postmenopausal 
women in a randomized, double-blind, dout~le-crossover study. Data = % 
change Item respective pretreatment values. 
CEE Simvastatln CEE/SLmvastatm 
LDL-C 1, = 11" 24 ~ 14 `~ 33 ~ 13"' 
ApoB 8 ~ 8" 23 ~ t0' ' 28 = 11" " 
PAl-1 22 ± 47'* .27 r 85 23 ~- 42-" 
'P - O 001, "'P - O 00.5 ""P . O 02 vs respochvo prelroatment basehne values: " P 
0 an5 vs CEE 
Only therapy including CEE reduced PAl-1 antigen levels, despite a 
greater effect of slm,,d~idon on reductiL, n in LDL-C and apolipoprotein B 
levels Further, there was no synergism of combined CEE and simvcslalin 
therapy on PAI-t levels. These data suggest that estrogen reduces PAl-1 
levels independent of changes in LDL. This primary effect of CEE on libn- 
nolytic potential may favor its use in hypercholesterolemic postmenopausal 
women, even it they are already on lipid-lowering therapy. 
11:30 
1 844-5J  Low-Dose  Estrogen Improves  Serum Lipids,  
Homocystelne, and F ibr ino lys ls  Wi thout  Alter ing 
Markers of  Hemostas is  in E lder ly Men 
S. Girt. P.D. Thompson, J.H. Centers, P. Taxel, J. elves. R. Allen, G. Ens. 
A,H.B. Wu. D.D. Waters. Hartford Hospital, University of Connecticut. 
Hartford. CT. USA 
The effect of estrogen on cardiovascular isk factors in men is not well defined. 
We measured hpopretoms, low.density hpoprolem (LDL) subclasses and 
part,tie size, hpopreloin (a), homocystemo (Hcys), and markets of thremboszs 
and fibnnolysis in 22 oealthy o!derly men ~ago 74 ~ 3 years, mean 
SO), before and alter 9 weeks of treatment with 05, t n, ~ mg,'day O1 oral 
m~cromted 17/~-estradiol 
Restdt~: LDL-C I-6%), apo.B ( 9%), fnglyceride ( 5%), VLDL-TG 
( - ! 9%) 8nd Ho/s ( - 11%) coneenffahons decreased w~th estradtot, whereas 
HDL-C (*14%) and HDL~-C (*55%) increased Lipoprotein (a) d~d not 
ch,~nge. Fibenogen (13%)  and p!asmln(~gen activator inhibitor.1 (PAl.l) 
(26%)  C~noeflf~ations decreasecl There were no changes ~n thrombotK: 
matkem including thrombln-ant!thrembm I!1 complex, prothrombm fragment 
t 2, O.dim0r, anhthfombm activity, preteln~C an~ S and yon Willebrand factor 
set!pen 
Va~btes Pte-eli1~ogen PO-~t~E~OO~I~, % Ch~lnge p vah~e 
(rne<tn ~ SD) irl~an ~ SOl 
LDL-C~t  14t ~ 2t] 132 ~ 30 63 ~ 12 = 0007 
IG mgd~ t30 s ~ 11.~ ~ 41 4 7 ~. ~0 : O 01 
HDL.C ~.'dt 47 t 0 S3 t I0 .t4 z 12 -1) 001 
HDL3.C n~'~l 23 ~ 13 29 ~ 13 .55 : 72 -0003 
HDL3"C m~2/dl 30 ~ ? 27 ~ (~ a 4 ~ tO ; 0 001 
LOLs~e (nml 207 ~O6 2oa ~ 06 9fi ~ a o0ot 
Hc'y~ ti,M) 67 ~ 3 76 ~ 2 I 1., 09 - OOOt 
CortCtu$iOn. We conclude that k'~v (~se estrogen in men reduces low-den- 
sity hpoprotems, homom/steine tibnn(~en and PlA-1 concentrations w~thout 
.ncfeas=ng markers of thrombotic ~sk 
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~ Lipoprotein(a), Stability of Coronary Reperfuslon 
and Efficacy of Thrombolytic Therapy 
AW Harder. G.J. Davies. Card~otogy D~.~s~en. RPMS Hammersm~th 
HOSl~tal London. UK 
Background: Lq:~,c'~retemt:t~ ',Lpa) promotes atherothrembos=s, however, stud- 
~es dunncj acute my~T, ard~al ..-ttarct=on (AMI) remain mcenclusnte We mves- 
bgatecl the relationship between Lpa and efficacy O1 thromb~lyl~c therap'y 
dunng AM= 
,~c-~; :  Twenty six patients 117 men. 9 women, mean age 57 : 2 years) 
admitted with AM| re~mved i v t-PA (30-60 Mega Units) w~thm 6 hours at the 
onset of Symptoms Coronary recanai=zat~on (TIMI grade 3) was assessed 
by senal adenography and ~n~nuou~ 2 channel ST segment recording was 
used to momtor the stabddy of coronary reperfusmn All pat~enLs received 
oral aspmn and =v hepann Baseline pretreatment Lpa and serum hp~d 
~eveLs were measu(.'~cl Patients ,~ere dtvldecl =n 2 groups: Group 1 ILpa 
levels ::25 mg.,'dl, n = 12) and Group 2 ILpa levels - 25 mg.'dl, n = 14) 
Resuits Age. sex. treatment delay from symptom onset. 90 minute TIMI 
grade and hp=ds levels ~ere similar ~n the 2 groups However. coronary 
recanahzafton time (mean : SD) was significantly prolonged cn group 1 
compared to patients m group 2 t51 = 16 vs 30 ; 17 rain p = 005) 
Recanalizahon t~me correlated pos=hvely w~th Lpa levels (r . 0.9. p ~ 0001 ). 
The number (5 : 1vS. 1 =05.  p - 002) and magmtude (31 ~: 1 mmvs. 
1.2 ~ 1 ram. p .  005) OI recurrent ST elevahon following thrombelysls was 
greater m grOup 1 cOmpared to group 2 
Conclusions: Elevated Lpa =s assooated with delayed and unstable coro- 
naw repedus~on toltowmg ~ v tPA 
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[ 845- i_~ I Rates and Predictors of Embolic Events Following 
Electrical Cardloverslon 
F. Genhle, B.K. Khandhena, KR. Bailey. C Lohse. J.8. Seward. A Jamd 
Taiik. Mayo Chn~c and M,tVO Foundat;on. Rochester. Mmnesota. USA 
Wide vanations (1-7%) in reported rates of embolic events lEE) following 
electrical cardioversion (ECV) exist in the literature. To evaluate EE nsk in 
the Mayo ECV practice, all ECVs (1053. 66% male. mean age 66 = 12.5 
years) between 1990-1994 were studied. Patient as well as atrial tibnllafion 
and anticoagulation (AC) characteristics were recorded. Adequate AC was 
defined as therapeutic International Normalized Ratio / Partial Thromboplas- 
tin -time. AC consisted of warfarin (63.0%). heparin (118%). born (15.9%), 
and none (9.3%). Successful ECV was achieved in 892 pts (85%) who form 
the basis for analysis. The rat3 of EE occurrence within 30 days was 0.78% 
(CI 0.32-1.62%). Two (2.1%) of these occurred in 94 no-AC pts (p = 0.012 
compared to AC pts) The rates of EE wore 027% m ad~uatety ant=co. 
agulated pls versus 1 68% ,n m~dequatety anllcoagutated pts (p = 0 0491 
All 7 events occurred =r, the 51% pts with hypedens~on (p = 0 OCt. ) Four 
occurred in 142 diabetic pts iP 0 001 ) History of coronary affery d~sca~.c~ 
and hyperl=p=dem~& were also segndcant (p 005) corretat~ ot EE Two 
O1 7 events OCCurred among 31 pts with severe letl atna! enfarsement (p .  
0 05) 
Cantles!ads 1) Ovmal! rate of EE following ECV m 0 78%= 2) adequate 
AC at the t~me O1 ECV results in lower rates o1 EE (027%); 3) hypertens~Onr 
d~abetes, and severn loft at~!! enla~rgement am associated with h igher  rates 
O1 EE following ECV: and 4) higher rates of EE (2 t%) are noted m pt~ 
not re~oiwng any AC ECV is ~ safe procedure when pts are adequately 
anl=coagutated 
10:45 
~ Hypertens!on Strongly Predict= Early Relapse Atter 
Elective Card!ovemlon of Air!a! Fibrillation 
L O'Toele, A. Wilhams, TR D ,Shaw, IR  Starkey, DB Nodhndge Depfot 
Card~o/og~, Western General Hosl~fat, Ec~nburgh. UK 
Background There h~ been a marked recent mcrea~e =n the use O1 electwe 
DC Cardmvers=on IDCCV) for atnal flbnllstlon (AFt We reviewed our pract*ce 
dunng 1996 to identdy chmcal factors which predict maintenance ol sinus 
rhythm (SR) at st~, week follow up (FU) 
Method: Case note rewew of 88 elective admms~ons for DCCV 
Results: 40% O1 patients had hyperlens=on (PIT) 40'% O1 patients were 
taking am~octarone peer to DCCV Immediate mstoratfon at SR was ach~evecl 
=n 88% O1 attempts but only 47% ot the tctat had maintained SR at FU 
In the 63 patrents undergoing DCCV for the first time, tact'ore pred,.ctmg 
maintenance of SR at FU were re~ewecl Age. sex, the presence ot CAD. 
impaired LV function ard use at digoxln did not predict mmntenance at SR 
3=;.~,*.~n .-,I AF ~rongty predicted maintenance O1 SR at FU (AF clura0on - 6 
months 84%. • 6 montt's 32%; p ~ 0 001 ) as did a d=agnos~s of PiT (SR at FU 
PIT 27%, non-HT 70%; p ~ O001) and use et amiodarene (SR at FU 74% 
vs 38%, p = 0002) After adiustment for durahon of AF or use O1 am~odarone 
the relabonsh~p between a diagnosm of HT and tadure to maintain SR at FU 
became even stronger (duration ac~Jsled odds rat~o; HT vs non-HT pat=eats 
12.6; p - 0.001 amlodarone adius~ed odds rat~o .54: p = O 004) 
Cencl'.~on The pr~pomon O1 I-IT patients cn th~s senes =s h~ghe[ than 
reported pre'.qousty, but similar to that m population-based studies of AF The 
chance of maintaining SR after DCCV =n HT patients =s unacceptably low 
Measures to improve outcome include early DCCV and pre-treatment with 
am~oclarene 
11:00 
~ 845-3  i The  Cl inical  Exper ience  With the Metr lx Automat ic  
' Imp lantab le  Atr ia l  Def ibr i l lator  
R Tavem~er, L Jordaens For the Metnx Ir~,est~gators. Umversffafr 
Z~ekenhu~s Gent. Gent. Belgium 
Transven~us atnal defibnllahon has been shown to be efficacious for the 
acute termination of episodes of areal fibnllal~on (AF). However, no data 
exist as fo whether repeated transvenous defibnllatlon using an aulomstlC 
cmplantable atrial defibnllator (laD) would be efficamous. Therefor~ the pur- 
pose O1 this chmcal teal was to evaluate the clinical use O1 the Metnx lAD 
m patients (pts) with uprsod~c, symptomatic AF refrecto~/ tO drug therapy. 
The device and Its 3 leads system (Penmeter nght sinai, Penmeter cereno~ 
sinus delibnllat~on and right ventncular bipolar leads) were ~mplanted in St 
pts (40 mares and 11 females). On average these patients had taken 39 
ant~arrhylhm~c drags that had fa~led to control AF recurrence or were found 
to have intolerable s~de effect These pts were without significant StruC~urat 
head d~sease and shghtly enlarged nght stnum (mean LA size 4 4 ~ 0 8 
cm). Dunng the study penocl of 20 months (mean pt follow-up 259 : 138 
days), 41 pts have exbenenced 252 spontaneous AF episodes (SE) with 
an average of 6 episodes per patient Excluding the throe epcsode5 that 
were !rested dunng ADFT testing. 675 synchron=zc"d shocks have been de- 
livered for the remmmng 249 SE (average 27 shocks per epcsode) with no 
ewdenoe of ventncutar prearrhythm~a One pstcent had a shock dehvered 
and had subsequent spontaneous conversion pnor to full delivery of ther- 
apy. One pabent had 4 SE where AF recurred shodly after the sucCesstul 
conversions. Three of these episodes were terminated with pharmacologi- 
cal interventions and one episode was terminated spontaneously. D~l;~ from 
these 8 episodes, including the 3 treated dunng ADFT testing, were ex- 
cluded =n the efficacy calculabons. The device has successfully terminated 
95=0 of the episodes although some patients had AF recurrence ~hortty ~; 
tar successful detibnllation. Taking th~s recurrence of AF into consideret¢on. 
the clinical efficacy of the defibnllat~on therapy was 77.4%. One pabent. 
due to frequent SE (1-2 per week) unaffected by the device unden,~ent AV 
junctional ablation with permanent pacing Prompt termmatren of AF has 
